MedTrace Logo

MRG-001 in Patients With Alcoholic Hepatitis

NCT06307522 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-03-13

No results posted yet for this study

Summary

The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).

Conditions

  • Alcoholic Hepatitis
  • Acute Alcoholic Hepatitis

Interventions

DRUG

MRG-001

Patients will receive subcutaneous administration of MRG-001 at designated visits.

Sponsors & Collaborators

  • MedRegen LLC

    lead INDUSTRY

Principal Investigators

  • Ali R Ahmadi, MD PhD · MedRegen LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-09-01
Completion
2026-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06307522 on ClinicalTrials.gov